CA2874400A1 - Tricyclic compounds as kat ii inhibitors - Google Patents

Tricyclic compounds as kat ii inhibitors Download PDF

Info

Publication number
CA2874400A1
CA2874400A1 CA2874400A CA2874400A CA2874400A1 CA 2874400 A1 CA2874400 A1 CA 2874400A1 CA 2874400 A CA2874400 A CA 2874400A CA 2874400 A CA2874400 A CA 2874400A CA 2874400 A1 CA2874400 A1 CA 2874400A1
Authority
CA
Canada
Prior art keywords
optionally substituted
halogen
pharmaceutically acceptable
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2874400A
Other languages
English (en)
French (fr)
Inventor
Amy B. Dounay
Jamison B. Tuttle
Patrick R. Verhoest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA2874400A1 publication Critical patent/CA2874400A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
CA2874400A 2012-06-15 2013-06-03 Tricyclic compounds as kat ii inhibitors Abandoned CA2874400A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261660142P 2012-06-15 2012-06-15
US61/660,142 2012-06-15
PCT/IB2013/054570 WO2013186666A1 (en) 2012-06-15 2013-06-03 Tricyclic compounds as kat ii inhibitors

Publications (1)

Publication Number Publication Date
CA2874400A1 true CA2874400A1 (en) 2013-12-19

Family

ID=48875701

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2874400A Abandoned CA2874400A1 (en) 2012-06-15 2013-06-03 Tricyclic compounds as kat ii inhibitors

Country Status (15)

Country Link
US (1) US20150175603A1 (cg-RX-API-DMAC7.html)
EP (1) EP2861593A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015523352A (cg-RX-API-DMAC7.html)
KR (1) KR20150007352A (cg-RX-API-DMAC7.html)
CN (1) CN104364253A (cg-RX-API-DMAC7.html)
AU (1) AU2013276165B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014030507A2 (cg-RX-API-DMAC7.html)
CA (1) CA2874400A1 (cg-RX-API-DMAC7.html)
HK (1) HK1206734A1 (cg-RX-API-DMAC7.html)
IL (1) IL236241A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN09826A (cg-RX-API-DMAC7.html)
MX (1) MX2014014808A (cg-RX-API-DMAC7.html)
RU (1) RU2014146509A (cg-RX-API-DMAC7.html)
SG (1) SG11201407389QA (cg-RX-API-DMAC7.html)
WO (1) WO2013186666A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI693227B (zh) 2014-04-23 2020-05-11 日商田邊三菱製藥股份有限公司 新穎二環性或三環性雜環化合物
CN106349241B (zh) * 2015-07-15 2020-04-21 上海翰森生物医药科技有限公司 具有hsp90抑制活性的三唑衍生物及其制备方法和应用
EP3372601B1 (en) 2015-10-22 2022-09-21 Mitsubishi Tanabe Pharma Corporation Novel bicyclic heterocyclic compound
HRP20221020T1 (hr) 2018-07-20 2022-11-11 Grünenthal GmbH Supstituirani derivati triazolo kinoksalina
CN111196817B (zh) * 2018-11-19 2021-06-11 四川大学华西医院 作为brpf1抑制剂的三环化合物
TWI880049B (zh) * 2020-12-04 2025-04-11 美商美國禮來大藥廠 Kras g12c抑制劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2316072B (en) * 1996-08-05 2000-05-10 Pharmacia Spa Pyrrolo[3,2-c]quinoline derivatives
JP5643818B2 (ja) * 2009-06-18 2014-12-17 ファイザー・インク Ｋａｔｉｉ阻害剤としての二環式および三環式化合物
WO2012073146A1 (en) * 2010-12-01 2012-06-07 Pfizer Inc. Kat ii inhibitors

Also Published As

Publication number Publication date
EP2861593A1 (en) 2015-04-22
BR112014030507A2 (pt) 2017-06-27
WO2013186666A1 (en) 2013-12-19
KR20150007352A (ko) 2015-01-20
HK1206734A1 (en) 2016-01-15
CN104364253A (zh) 2015-02-18
MX2014014808A (es) 2015-02-12
RU2014146509A (ru) 2016-08-10
AU2013276165B2 (en) 2015-07-16
US20150175603A1 (en) 2015-06-25
IN2014DN09826A (cg-RX-API-DMAC7.html) 2015-07-31
JP2015523352A (ja) 2015-08-13
SG11201407389QA (en) 2015-02-27
AU2013276165A1 (en) 2014-11-27
IL236241A0 (en) 2015-02-01

Similar Documents

Publication Publication Date Title
EP1490364B1 (en) 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
AU2003214414B2 (en) Azaindoles as inhibitors of c-Jun N-terminal kinases
KR101390023B1 (ko) 키누레닌 아미노트랜스퍼라제 ｉｉ 억제제로서 이환식 및 삼환식 화합물
AU2013276165B2 (en) Tricyclic compounds as KAT II inhibitors
JP2019520396A (ja) Ｒｏｃｋ阻害剤としてのスピロ縮合環尿素
JP7017801B2 (ja) Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害
CA3050853A1 (en) Heterocyclic spiro compounds as magl inhibitors
CA3010900A1 (en) Spiroheptane salicylamides and related compounds as inhibitors of rock
CN110831936A (zh) 具有dub抑制剂活性的取代氰基吡咯烷
TW202340191A (zh) 作為ＣＢＰ／ｐ３００抑制劑之四氫－咪唑並喹啉化合物
CA2911693C (en) 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
FR2731708A1 (fr) Derives de piperidine, leur procede de preparation et leur application en therapeutique
EP2616460B1 (en) Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine.
EP3679039A1 (en) Tyrosine analogues derivatives as rho- kinase inhibitors
CA2819106C (en) Kat ii inhibitors
CZ139298A3 (cs) Amidinové a isothiomočovinové deriváty jako inhibitory synthasy oxidu dusičného
CN111201226A (zh) 环状被取代的咪唑并[4,5-c]喹啉衍生物
TW202345812A (zh) 作為組蛋白去乙醯酶6抑制劑之1,3,4-㗁二唑衍生化合物及其用途
JP2021512942A (ja) トリアゾール、イミダゾールおよびピロール縮合ピペラジン誘導体、およびｍＧｌｕ５受容体のモジュレータとしてのそれらの使用
JP2016505584A (ja) ダウン症候群及びアルツハイマー病に関連する認知欠損の治療のための、ｄｙｒｋ１ａタンパク質阻害剤としての３，５−ジアリールアザインドール類
CN122070289A (zh) 羟基去甲氯胺酮类似物及其用途
JP2025530834A (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物およびその使用
CN116675641B (zh) 他克林-司来吉兰衍生物及其制备方法和应用
JP7333420B2 (ja) トリアゾロピリミジン化合物及びその塩、組成物と使用
HK40075698B (en) 1,3,4 oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141121

FZDE Discontinued

Effective date: 20170605